Monogram Health, a tech-backed benefit management company, has raised $375 million in fresh funding. CVS Health, Humana, SCAN Health Plan, Cigna Ventures, and Memorial Hermann Health System are the strategic investors in the round.
Other participants include First Cressey Ventures, TPG Capital, Pura Vida Investments, Northwest Ventures Partners, and Heritage Group. Monogram Health will use the proceeds from the fresh funding to deploy its clinical services and delivery system for kidney and chronic disease care in the home.
“This latest milestone growth funding round with substantive new and existing partners is driven by our disciplined commitment to, and demonstration of, outstanding clinical results. These better quality outcomes for patients are made possible by our transformative approach to offering in-home, evidence-based nephrology and polychronic care,” said Dr. Bill Frist, Monogram’s board chair.
For patients with polychronic conditions, such as chronic kidney disease and end-stage renal disease, Monogram Health improves patient outcomes and quality of life while lowering medical costs across the healthcare continuum, enhancing access and affordability for all.
For those with renal and co-occurring metabolic diseases, this ground-breaking treatment style completely alters the way medical care is provided.
“Kidney disease impacts a disproportionate share of disadvantaged communities and communities of color. Monogram has made bold strides in offering patients and families enhanced access to much-needed health services while substantially improving the overall affordability of their care,” said Senator Bill Frist.
Monogram is implementing a unique, integrated strategy for providing in-home care.
Access to the kind of specialist care that the healthcare startup offers is crucial for the more than 37 million American people who suffer from chronic kidney disease.
The company’s prominent market-based clinicians, directed by physicians and nurse practitioners and backed by registered nurses, social workers, pharmacists, and care management teams, are responsible for its transformative, high-touch, and in-home models.
To personalize the experience and care for Monogram patients in approximately 4,000 U.S. communities across 34 states, utilization management teams concentrating on hospitalizations and discharge management offer added support for these clinicians and clinical specialists.
“Everything we do is designed to improve access to health care and health outcomes for polychronic patients by supporting their individual needs in their own homes, transforming the patient experience, especially for those historically underserved,” said Mike Uchrin, CEO and Co-Founder of Monogram Health.
With its new strategic syndicate, Monogram’s investor base now serves over 30 percent of Medicare Advantage members nationwide. It supports over 40 percent of the U.S. population, uniquely positioning the company to help those living with chronic kidney disease and their related metabolic disorders.
